Company intelligence / Profile preview

Respirion Pharmaceuticals

Iluka, Western Australia, Australiarespirionpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Respirion's lead product, an inhaled therapy for cystic fibrosis, has shown promising results in an early clinical study carried out with the Western Australian Department of Health. The company is developing a novel inhaled treatment that combines a widely used antibiotic with a biofilm disrupting agent.

Therapeutic areas: PulmonologyInfectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

1 asset

RSP-1502

Phase 2

Indications: Cystic fibrosis lung infections

Partnerships

Medical Research Commercialisation FundUS Cystic Fibrosis Foundation

Beyond the preview

Go deeper on Respirion Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respirion Pharmaceuticals.

Explore the full profile